Pancreatic ductal adenocarcinoma: Current and evolving therapies
MetadataShow full item record
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.
Showing items related by title, author, creator and subject.
Quality of life in women during and after treatment for breast cancer: a systematic review of qualitative evidenceDevi, M.; Hegney, Desley (2011)Background: Breast cancer is the most common cancer in women. With increasing numbers of women surviving breast cancer, there is a need to move beyond the traditional ways of evaluating clinical outcomes and include ...
Chandolu, V.; Dass, Crispin (2013)Context: One of the leading causes of cancer-associated deaths in most men and women in the Western world is lung cancer. There are various types of treatments depending on the type and the stage of the cancer. A recent ...
Kemp, A.; Preen, D.; Saunders, C.; Boyle, F.; Bulsara, M.; Malacova, Eva; Roughead, E. (2014)Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities ...